Interstitial Lung Diseases treatment prescription practices among pulmonologists in India: A prospective multicentre observational study (India-ILD care study).

@article{hadda2026interstitial,
  title = {{Interstitial Lung Diseases treatment prescription practices among pulmonologists in India: A prospective multicentre observational study (India-ILD care study).}},
  author = {Vijay Hadda and Avishek Layek and Pawan Tiwari and Saurabh Mittal and Nipun Malhotra and Maroof Ahmad Khan and Prasanta Raghab Mohapatra and Sourin Bhuniya and Raj Kumar and Sonam Spalgais and Dharm Prakash Dwivedi and Vishnukanth Govindaraj and Saurabh Karmakar and Lovely Sinha and Prakhar Sharma and Girish Sindhwani and Devasahayam J Christopher and Barney Isaac and Sheetu Singh and Bharat Bhushan Sharma and Amitabha Sengupta and Pradyot Sinhamahapatra and Nazia Mehfooz and Tehleel Altaf Shera and Vikas Marwah and Manu Chopra and Ajoy Kumar Behera and Ranganath Ganga and Puneet Saxena and Geetika Yadav and Md Arafat Hussain and Tejas Menon Suri and Irfan Shekh and Karan Madan and Anant Mohan and ICMR’s Network of Pulmonary Fibrosis (INPF) collaborators},
  journal = {PloS one},
  year = {2026},
  month = oct,
  doi = {10.1371/journal.pone.0360678},
  url = {https://europepmc.org/article/MED/42912795},
  note = {CC BY},
}

TY  - JOUR
TI  - Interstitial Lung Diseases treatment prescription practices among pulmonologists in India: A prospective multicentre observational study (India-ILD care study).
AU  - Vijay Hadda
AU  - Avishek Layek
AU  - Pawan Tiwari
AU  - Saurabh Mittal
AU  - Nipun Malhotra
AU  - Maroof Ahmad Khan
AU  - Prasanta Raghab Mohapatra
AU  - Sourin Bhuniya
AU  - Raj Kumar
AU  - Sonam Spalgais
AU  - Dharm Prakash Dwivedi
AU  - Vishnukanth Govindaraj
AU  - Saurabh Karmakar
AU  - Lovely Sinha
AU  - Prakhar Sharma
AU  - Girish Sindhwani
AU  - Devasahayam J Christopher
AU  - Barney Isaac
AU  - Sheetu Singh
AU  - Bharat Bhushan Sharma
AU  - Amitabha Sengupta
AU  - Pradyot Sinhamahapatra
AU  - Nazia Mehfooz
AU  - Tehleel Altaf Shera
AU  - Vikas Marwah
AU  - Manu Chopra
AU  - Ajoy Kumar Behera
AU  - Ranganath Ganga
AU  - Puneet Saxena
AU  - Geetika Yadav
AU  - Md Arafat Hussain
AU  - Tejas Menon Suri
AU  - Irfan Shekh
AU  - Karan Madan
AU  - Anant Mohan
AU  - ICMR’s Network of Pulmonary Fibrosis (INPF) collaborators
PY  - 2026
DA  - 2026/10/23
JO  - PloS one
DO  - 10.1371/journal.pone.0360678
UR  - https://europepmc.org/article/MED/42912795
AB  - Background and objectives  There is limited data on prescription behaviour and compliance with interstitial lung disease (ILD) guidelines among pulmonologists. This study aimed to evaluate ILDs treatment prescription behaviour in India.Methods  Prescriptions of treatment-naive ILD patients from 13 tertiary care hospitals were reviewed and classified as guideline compliant (GCP) or non-compliant (GNCP) for pharmacological and non-pharmacological components. Change in forced vital capacity (FVC), diffusing capacity (DLCO), and six-minute walk distance (6-MWD) at 6 and 12 months were compared between GCP and GNCP.Results  After screening 720 participants, 425 treatment-naïve ILD patients (56.7% female; mean age 51.7 years) were included. Connective tissue associated-ILD (CTD-ILD) was the most common diagnosis (36.2%), followed by hypersensitivity pneumonitis (17.4%), idiopathic pulmonary fibrosis (IPF, 13.9%), interstitial pneumonia with autoimmune features (13.9%), and sarcoidosis (8.2%). GCP rates for ILD specific pharmacotherapy were 83%, 74.7%, and 93.5% for IPF, CTD-ILD, and sarcoidosis, respectively. In IPF, patients with GCP had significantly lower FVC decline at 12 months compared to the GNCP (0.06 L vs. 0.25 L; p = 0.02). There was huge care-gap in non-pharmacological advice with 13.2%, 7.1%, 10.2% and 4.2% of eligible cases were advised vaccination, pulmonary rehabilitation, antigen avoidance, and lung transplantation counselling, respectively.Interpretation and conclusions  India-ILD care study revealed a huge care gap with significantly under-prescription of non-pharmacological components. These results highlight the urgent need for organized implementation strategies including dissemination of guidelines, and a greater emphasis on a structured management protocol that includes both pharmacological and non-pharmacological treatment to optimize outcomes for ILD in India.
SN  - 1932-6203
ER  -